NYKD Stock Overview
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nykode Therapeutics AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr16.60 |
| 52 Week High | kr34.76 |
| 52 Week Low | kr16.28 |
| Beta | 1.4 |
| 1 Month Change | -29.96% |
| 3 Month Change | -42.99% |
| 1 Year Change | -33.44% |
| 3 Year Change | -66.97% |
| 5 Year Change | n/a |
| Change since IPO | -16.16% |
Recent News & Updates
Shareholder Returns
| NYKD | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -15.3% | -9.1% | 0.8% |
| 1Y | -33.4% | -64.5% | 0.06% |
Return vs Industry: NYKD exceeded the Norwegian Biotechs industry which returned -64.8% over the past year.
Return vs Market: NYKD underperformed the Norwegian Market which returned 0.6% over the past year.
Price Volatility
| NYKD volatility | |
|---|---|
| NYKD Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in NO Market | 11.9% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: NYKD is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: NYKD's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 165 | Michael Engsig | https://nykode.com |
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10
Nykode Therapeutics AS Fundamentals Summary
| NYKD fundamental statistics | |
|---|---|
| Market Cap | kr4.91b |
| Earnings (TTM) | -kr519.89m |
| Revenue (TTM) | kr144.70m |
33.9x
P/S Ratio-9.4x
P/E RatioIs NYKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYKD income statement (TTM) | |
|---|---|
| Revenue | US$12.99m |
| Cost of Revenue | US$7.08m |
| Gross Profit | US$5.91m |
| Other Expenses | US$52.58m |
| Earnings | -US$46.67m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 15, 2023
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 45.52% |
| Net Profit Margin | -359.29% |
| Debt/Equity Ratio | 0% |
How did NYKD perform over the long term?
See historical performance and comparison